OXFORD, England--(BUSINESS WIRE)--Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, has today announced the appointment of Dr. Laura Trespidi as Chief Development Officer.
Dr. Trespidi brings more than 30 years’ of experience in global pharmaceutical and biotechnology companies, across clinical product development and manufacturing, from pre-clinical research through to market approvals and global product launches. Most recently as Senior Vice President, Chemistry, Manufacturing and Controls (CMC), Supply Chain and Technical Operations at Summit Therapeutics, Dr. Trespidi has successfully led global CMC and External Manufacturing teams through the development and market preparedness of investigational medicines, including end-to-end supply chain and manufacturing readiness and expansion.
Dr. Trespidi’s expertise extends further to formulation development, technology transfers, outsourcing and offshoring, with additional experience developing and executing change management strategies. Throughout her career, Dr. Trespidi has played a pivotal role in over 40 first-in-human clinical trials and pre-clinical trials, as well as contributing to four New Drug Applications (NDA) and market approvals, and over 40 Investigational New Drug (IND) applications.
The world-class leadership and technical expertise gained at Summit Therapeutics and other leading companies such as Mundipharma, Shire Pharmaceuticals and GlaxoSmithKline, will enable Dr. Trespidi to support the progression and development of Beckley Psytech’s investigational assets, including the proprietary formulations of intranasal 5-MeO-DMT, currently in Phase 1 studies.
Dr. Trespidi received her PhD. in Pharmaceutical Science from the University of Milan, Italy; an M.Sc. in Medicinal Chemistry and Biochemistry from the University of North Carolina, US; and in 2008 she received an M.B.A from the Open University Business School, UK. Dr. Trespidi has authored a number of papers published in peer-reviewed journals and is a member of several scientific societies and associations.
Cosmo Feilding Mellen, CEO of Beckley Psytech, said: “Dr. Trespidi joins us as our Chief Development Officer at an exciting time, with our lead drug candidates in Phase 1 clinical studies. Laura’s impressive track record and expertise across clinical development and manufacturing will be invaluable, as Beckley Psytech continues to grow and progress its clinical pipeline in this groundbreaking area of medicine.”
Dr. Laura Trespidi, CDO of Beckley Psytech, said: “I am thrilled to be joining Beckley Psytech at such a transformative time for the Company and for psychedelic medicines. Beckley Psytech’s innovative pipeline has real potential to offer meaningful improvement to patients’ lives, and I am looking forward to working alongside a world-class team to turn this vision into a reality.”
-Ends-
Beckley Psytech - www.beckleypsytech.com
Beckley Psytech is a clinical stage privately held company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases. Our vision is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients with high unmet medical need around the world suffering with treatment resistant depression, and other profoundly debilitating neurological conditions. Beckley Psytech was founded in 2019 leveraging some of the expertise developed over more than 20 years by the Beckley Foundation, an independent non-profit and world leader in psychedelic medicine research, and is based out of Oxford, United Kingdom.
